Novo Nordisk moves HC to bar Sun Pharma from manufacturing semaglutide
This story was originally published at 11:31 IST on 9 December 2025
Register to read our real-time news.Informist, Tuesday, Dec. 9, 2025
--Novo Nordisk moves HC to bar Sun Pharma from manufacturing semaglutide
NEW DELHI – Novo Nordisk AS Tuesday moved the Delhi High Court, seeking to bar Sun Pharmaceutical Industries Ltd. from manufacturing and selling its version of diabetes and obesity drug 'semaglutide'. In a brief hearing, Justice Tejas Karia placed Novo Nordisk's plea to be heard by Justice Manmeet Pritam Singh Arora, who had heard a similar plea against Dr. Reddy's Laboratories Ltd. and its contract manufacturer OneSource Speciality Pharma Ltd. on the similar issue regarding 'semaglutide' drug, on Wednesday.
On Dec. 2, Justice Arora had rejected Novo Nordisk AS's plea for an interim injunction and allowed Dr. Reddy's Laboratories and OneSource Speciality to manufacture their version of diabetes and obesity drug 'semaglutide' and export the same to countries where Novo Nordisk have not been granted a patent of the drug. However, Dr. Reddy's Laboratories and OneSource Speciality were not allowed to sell their version of 'semaglutide' drug in India till March 2026, when Novo Nordisk's patent for the drug will expire.
Justice Manmeet Pritam Singh Arora said that there was a credible challenge to the validity of Novo Nordisk's patent on drug 'semaglutide'. Currently, Novo Nordisk sells 'Wegovy' and 'Rybelsus' using its patent on the drug 'semaglutide' and received the Central Drugs Standard Control Organisation's approval for its 'Ozempic'.
Danish drugmaker Novo Nordisk held a primary consumption patent for 'semaglutide', which expired in September 2024. However, Novo Nordisk still held the secondary patent in India relating to the manufacturing process and delivery mechanism of 'semaglutide' drug, which remained valid till March 2026.
At 1125 IST, the shares of Sun Pharmaceutical Industries Ltd. were down 0.2% at INR 1,791.80 on the National Stock Exchange. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Reported by Surya Tripathi
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
